Topical Patch Rapidly Clots Blood

A topical hemostatic closure system employs proprietary microporous polysaccharide hemospheres (MPH) technology to instantly dehydrate blood at the wound site, creating rapid hemostasis and resilient clotting.

MPH technology presents a new process for producing almost instantaneous hemostasis at wound sites, even in the presence of profuse bleeding. The technology consists of an engineered biopolymeric, microporous particle with a controlled pore size, which is designed to act as a sieve to dehydrate the blood and thus serve to accelerate the natural clotting process.

Using this technology, clotting has been demonstrated to initiate within as little as 30 seconds to one minute, compared to as much as 30 minutes required by traditional hemostats. Applied topically, the MPH particle gels rapidly with no tissue irritation, creating a protected environment for hemostasis and healing. This action significantly reduces the necessary time for hemostasis in comparison to manual compression in vascular access procedures

The bead-like particles are derived from plant-based biomaterials with an extensive history of use in humans. The molecular exclusion properties of the bead create a high concentration of platelets and other constituents on the exterior surface as the blood is dehydrated. Acting as a molecular sieve, the bead absorbs fluids in the blood, as proteins and cellular constituents adhere to its surface. These gelled, compacted cells accelerate the normal clotting cascade. The expanded beads and their load of platelets and solids become part of a clot that initial tests have shown to be more resilient even than a purely natural clot.

The MPatcH vascular closure device is the product of Medafor (Minneapolis, MN, USA) and is available to markets in Europe, Africa, the Middle East, Central and South America, and Asia-Pacific.

"MPatcH received a highly favorable response at the Paris Course on Revascularization in May [2006], and we are very excited about its launch into the international arena,” said Gary Shope, Medafor CEO. "We have long seen the need for a simple and efficacious closure system for vascular procedures both domestically and internationally.”



Related Links:
Medafor